Anagrelide retard

DRUG2 trials

Sponsors

AOP Orphan Pharmaceuticals AG

Conditions

Essential ThrombocythaemiaEssential Thrombocythemia

Phase 3

Anagrelide Retard vs. Placebo: Efficacy and Safety in At-risk Patients With Essential Thrombocythaemia

CompletedNCT01230775

AOP Orphan Pharmaceuticals AGEssential Thrombocythaemia

Start: 2010-12-31End: 2015-01-31Updated: 2016-05-26

Anagrelide Retard in Essential Thrombocythemia

CompletedNCT02076815

AOP Orphan Pharmaceuticals AGEssential Thrombocythemia

Start: 2014-02-28End: 2015-04-30Updated: 2015-07-29